PA5-30622

antibody from Invitrogen Antibodies

Targeting: GOLM1 bA379P1.3, C9orf155, FLJ23608, GOLPH2, GP73

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-30622

Provider

Invitrogen Antibodies

Product name

GOLPH2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: HeLa, HeLa membrane extract, DU145. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.16 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells.

Bellissimo T, Tito C, Ganci F, Sacconi A, Masciarelli S, Di Martino G, Porta N, Cirenza M, Sorci M, De Angelis L, Rosa P, Calogero A, Fatica A, Petrozza V, Fontemaggi G, Blandino G, Fazi F
Cell death & disease 2019 Jan 8;10(1):17

---

Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, Petrozza V, Giangaspero F, Pescarmona E, Facciolo F, Venuta F, Marino M, Blandino G, Fazi F
Molecular cancer 2017 May 10;16(1):88

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of GOLPH2 in methanol-fixed HeLa cells using a GOLPH2 polyclonal antibody (Product # PA5-30622) (Green) at a 1:500 dilution. Alpha-tubulin filaments were labeled with Product # PA5-29281 (Red) at a 1:2000.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry-Immunofluorescence analysis of GOLPH2 was performed in HeLa cells fixed in 4% paraformaldehyde at RT for 15 min. Green: GOLPH2 Polyclonal Antibody (Product # PA5-30622) diluted at 1:500. Red: phalloidin, a cytoskeleton marker. Blue: Hoechst 33342 staining. Scale bar = 10 µm.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 Expression profiling of putative targets of miR-145-5p in Thymoma versus normal Thymus tissues. a Box plot showing the modulation of miR-145-5p expression in the group of 6 tumors and 3 normal samples used to evaluate gene expression profiling. b Unsupervised clustering analysis representing the expression of putative targets of miR-145-5p inversely correlated to miR-145-5p expression in thymic tumors compared to normal tissues. c Validation by RT-qPCR of mRNA expression of three putative targets of miR-145-5p, Golm-1, Psat-1 and CDH2, in the same dataset of samples used for gene expression profiling (2 normal tissues and 6 tumors). d - e Table showing the number of Golm-1 and CDH2 positive (score > 1) and negative (score 0) samples in the subset of normal and tumor tissues of each histotype. f Table showing the number of Golm-1 and CDH2 co-expressing samples in the subset of tumor tissues of each histotype. g Expression of Golm-1 and CDH2 protein by immunohistochemistry (IHC) analysis in a representative normal thymus and tumor tissues of each histotype

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 Overexpression of miR-145-5p in a Thymic Carcinoma (TC1889) cell line. a RT-qPCR to evaluate the expression levels of miR-145-5p inversely correlated (Golm-1 and Psat-1) and positively correlated (Pcdh9 and Cldn1) genes after miR-145-5p overexpression in TC1889 cells. b Western-blot analysis of Golm-1 and Synaptophysin (SYP) proteins after 72 h and 96 h of miR-145-5p overexpression in TC1889 cells. c Morphological and IHC analyses for Golm-1 and Psat-1 of miR-145-5p overexpression in TC1889 cells after 144 h or 96 h respectively. d - e Evaluation of the impact of miR-145-5p overexpression or siRNA for Golm-1 (siGolm-1) in TC1889 by migration assay after 120 h and 72 h respectively. P-value was calculated by unpaired t -test and a value of P

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 4 Inhibition of HDAC activity releases miR-145-5p expression resulting in miR-145-5p target genes modulation. a RT-qPCR to evaluate the expression levels of miR-145-5p after 72 h of 3 mM VPA treatment of TC1889 cells. b Schematic representation miR-145-5p upstream genomic region (upper panel) and Chromatin Immunoprecipitation (ChIP) analysis (lower panel) to evaluate the histone H4 acetylation (H4Ac) status of R1 and R2 miR-145 upstream genomic regions (R1 located at -1500 bp and R2 located at -1000pb) after 24 h of 3 mM VPA treatment in TC1886 cells. The intronic region of CCNB1 gene (Int B1) was used as negative control. c RT-qPCR to evaluate the expression levels of Golm-1, EGFR, CDH2 and Psat-1 after 72 h of 3 mM VPA treatment of TC1889 cells. d Wester blot analysis to evaluate Golm-1, EGFR and SYP after 24 h and 48 h of 3 mM VPA treatment of TC1889 cells. e Morphological and IHC analyses for Golm-1, EGFR, CDH2 and Psat-1 after 72 h of 3 mM VPA treatment of TC1889 cells. P -value was calculated by unpaired t -test and a value of P